Drugmaker Pfizer on Monday said it would launch a less-expensive version of rival Johnson & Johnson’s (J&J) blockbuster immune disorder drug, Remicade.
Pfizer Inc’s version, called Inflectra, is to hit pharmacies late next month. It will be only the second so-called biosimilar drug available in the US.
Remicade, which has long been J&J’s top-selling drug, is approved for treating rheumatoid arthritis, psoriasis, colitis and other immune system disorders.
Biosimilars are near-copies of biologic drugs, which are very expensive injected medicines that are “manufactured” inside living cells, rather than by mixing chemicals together.
New York-based Pfizer said it would sell Inflectra at a 15 percent discount to the list price for Remicade.
J&J said in a statement it would compete with Inflectra “through a variety of innovative contracting options, discounts and rebates to payers, providers and pharmacy benefit managers” to keep Remicade affordable for patients.
The cost for Remicade varies, because the dosage depends on the patient’s weight, the immune disorder being treated and whether the patient is beginning treatment or on a lower maintenance dose, but it is roughly US$2,600 per month without insurance.
J&J said it gives insurers discounts and rebates on their costs, that many insured patients have very low copayments and that those without insurance can apply for financial aid.
Currently, there is only one biosimilar for sale in the US, Zarxio from Swiss drugmaker Novartis AG’s generic drug division, Sandoz. Zarxio was launched in September last year, at a 15 percent price discount to Amgen Inc’s Neupogen, which boosts white blood cell production to prevent infections in patients with cancer and a few other conditions.
US insurers, doctors and patients have been eager for access to cheaper versions of biologic drugs, which can cost US$100,000 or more annually. Last year, six of the 10 bestselling medicines by global revenue were biologics, with about US$49 billion in combined sales.
More than 20 biosimilar versions of seven different medicines are on the market in Europe. However, in the US, biosimilars have been delayed by the lengthy process of setting up rules for their approval, as well as lawsuits between drugmakers.
A 2010 law allows near-
copies of biologic drugs, known as biosimilars, after 12 years of market exclusivity for the original. However, so far the makers of original drugs facing biosimilar rivals have been trying to delay that competition with lawsuits over whether the original drug still has a patent in force that protects its monopoly.
In the case of Inflectra, litigation between Pfizer and J&J, which is based in New Brunswick, New Jersey, is continuing over whether Remicade still has a valid patent. A federal judge in August ruled the patent was invalid, but J&J is appealing that. If Pfizer loses the litigation, it would face substantial financial penalties because it is making what is called an “at-risk” launch of Inflectra.
Remicade is known chemically as infliximab. Inflectra will bear the chemical name infliximab-dyyb, as the US Food and Drug Administration requires that biosimilar drugs have a suffix attached to their name to distinguish the biosimilar from the original medicine.
Remicade has treated more than 2.6 million people worldwide since 1998, J&J said.
POOR INTERNAL CONTROLS: Insurance Bureau Director-General Shih Chiung-hwa said the company is expected to get back on track while its chairman is suspended The Financial Supervisory Commission (FSC) yesterday fined Shin Kong Life Insurance Co (新光人壽) NT$27.6 million (US$939,415) for a reckless investment that endangered its solvency, and suspended its chairman Eugene Wu (吳東進) for poor supervision. The penalty is the second-highest in a single case after Nan Shan Life Insurance Co (南山人壽) was fined NT$30 million in September last year and its chairman Du Ying-tzyong (杜英宗) suspended for two years, the commission said. In three rounds of special and regular examinations conducted since last year, the commission found that Shin Kong Life had given too much power to an asset and liability management committee
HEAVY INVESTMENT: Moody’s affirmed the firm’s ‘Aa3’ rating with a ‘stable’ outlook due to its leading position in the industry and ability to match customer requirements Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) revenue this year is expected to increase about 21 percent to NT$1.29 trillion (US$44.01 billion) from NT$1.07 trillion last year, driven by strong demand for advanced 5-nanometer and 7-nanometer chips mainly used in smartphones and high-performance computing devices, a Moody’s Investors Service report on Wednesday said. TSMC’s rate of revenue growth next year is to increase to 7.5 percent, the ratings agency said. The company, which supplies 5-nanometer chips for Apple Inc’s new iPad series, has introduced the advanced chips ahead of its competitors and gained a significant share of the market for the foundry industry’s
Sony Corp has cut its estimated Play Station 5 (PS5) production for this fiscal year by 4 million units, down to about 11 million, following production issues with its custom-designed system-on-chip (SOC) for the new console, people familiar with the matter said. The Tokyo-based electronics giant in July boosted orders with suppliers in anticipation of heightened demand for gaming in the holiday season and beyond, as people spend more time at home due to the COVID-19 pandemic. However, the company has come up against manufacturing issues, such as production yields as low as 50 percent for its SOC, which have cut into
O2O BICYCLE SHOW: The Taiwan Bicycle Show next year is to be online to offline, with forums, audio-visual conferences and livestreaming of the offline events Local bicycle makers expect demand to continue outpacing supply due to orders triggered by the COVID-19 pandemic, with some companies seeing orders back up through next year. “Next year is all full in terms of orders. Our lead time on components is one year,” Giant Manufacturing Co Ltd (巨大機械) chairwoman Bonnie Tu (杜綉珍) told a news conference in Taipei organized by the Taiwan External Trade Development Council (TAITRA) to announce next year’s Taipei Cycle Show. The pandemic has reduced bicycle supplies and increased demand around the world, Robert Wu (吳盈進), chairman of KMC (Kuei Meng) International Inc (桂盟國際), one of the world’s